Faecal Calprotectin Testing Market Size, Growth and Forecast 2032

Market Overview

The Faecal Calprotectin Testing Market is projected to grow from USD 201,112 million in 2024 to USD 332,839.48 million by 2032, at a compound annual growth rate (CAGR) of 6.5%.

The Faecal Calprotectin Testing Market is primarily driven by the increasing prevalence of gastrointestinal diseases, such as inflammatory bowel disease (IBD) and colorectal cancer, where early detection plays a crucial role in improving patient outcomes. The growing awareness about non-invasive diagnostic methods and the rising demand for personalized healthcare further support market growth. Advances in technology have led to the development of more accurate and efficient testing methods, making faecal calprotectin testing a preferred diagnostic tool. Additionally, the expanding geriatric population and the focus on early diagnosis and preventive healthcare are contributing to the market's expansion. Trends include the integration of faecal calprotectin testing with digital health solutions, enabling better disease monitoring and management. Furthermore, increasing healthcare investments in emerging markets and collaborations among diagnostic companies are expected to accelerate the adoption of faecal calprotectin testing, enhancing overall market dynamics in the coming years.

The Faecal Calprotectin Testing Market exhibits strong growth across various regions, with North America holding the largest market share due to advanced healthcare systems and high awareness of gastrointestinal diseases. Europe follows closely, driven by widespread adoption of non-invasive diagnostic methods and an aging population. The Asia-Pacific region is expected to experience significant growth, fueled by increasing healthcare investments and rising demand for diagnostic tools in emerging markets like China and India. Key players in the market include Epitope Diagnostics Inc., Hycult Biotech, Actim, Eagle Biosciences, Inc., OPERON, Svar Life Science, BÜHLMANN, DRG International Inc., ALPCO, and Diazyme Laboratories. These companies are actively contributing to the market's growth by introducing advanced diagnostic solutions and expanding their presence in various regions, enhancing the accessibility of faecal calprotectin testing worldwide.

Market Drivers

Rising Prevalence of Gastrointestinal Disorders

The increasing incidence of gastrointestinal diseases, particularly inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, is one of the primary drivers of the Faecal Calprotectin Testing Market. These chronic conditions require continuous monitoring, and faecal calprotectin testing has proven to be an effective tool for diagnosing and managing IBD. The global rise in colorectal cancer cases further amplifies the demand for non-invasive diagnostic methods like faecal calprotectin testing. For instance, the Crohn’s & Colitis Foundation has emphasized the importance of faecal calprotectin testing in monitoring IBD, highlighting its role in improving patient management. Early detection through such tests enables more effective management of these diseases, contributing to better patient outcomes and increasing the demand for such diagnostic solutions.

Non-Invasive Diagnostic Methods

As patients and healthcare providers increasingly prioritize non-invasive diagnostic options, faecal calprotectin testing has gained traction due to its ability to accurately assess inflammation in the gastrointestinal tract without the need for invasive procedures like colonoscopies. For instance, Calpro AS offers non-invasive faecal calprotectin test kits that are widely used for assessing gastrointestinal inflammation. This preference for non-invasive testing is largely driven by the convenience and lower associated risks, making faecal calprotectin a more appealing option for both patients and clinicians. The adoption of such tests continues to grow as more individuals seek reliable, efficient, and less disruptive methods for disease detection.

Technological Advancements

Technological innovations have significantly enhanced the accuracy, reliability, and speed of faecal calprotectin testing. Improved test kits, point-of-care diagnostic tools, and digital health integration enable quicker results and more precise disease monitoring. For instance, BÜHLMANN Laboratories has developed advanced faecal calprotectin test kits that provide rapid and accurate results, facilitating better disease monitoring. As a result, healthcare providers can offer more effective treatment plans and personalized care. Continued advancements in technology are expected to make faecal calprotectin testing even more accessible and efficient, driving greater adoption of these tests across healthcare settings.

Growing Focus on Preventive Healthcare

The increasing global focus on preventive healthcare and early diagnosis plays a pivotal role in the expansion of the Faecal Calprotectin Testing Market. Governments, health organizations, and healthcare providers are emphasizing early detection and proactive management of chronic diseases, which boosts the demand for tests that can identify conditions like IBD and colorectal cancer in their early stages. For instance, the National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing for the early detection and management of IBD, underscoring its importance in preventive healthcare. As more individuals seek preventive measures to safeguard their health, the need for accurate and accessible diagnostic solutions like faecal calprotectin testing continues to grow.

 Market Trends

Integration with Digital Health Solutions

One of the current trends in the Faecal Calprotectin Testing Market is the integration of faecal calprotectin tests with digital health platforms. This trend reflects the growing emphasis on data-driven healthcare, where test results can be monitored in real-time and shared with healthcare providers for more efficient management of gastrointestinal conditions. For instance, HealthNavigator has developed a digital health platform that integrates faecal calprotectin test results, allowing for real-time monitoring and improved patient management. The use of mobile health apps and cloud-based systems allows for continuous tracking of disease progression, enhancing patient care and enabling more personalized treatment plans. This integration is improving both patient engagement and clinical outcomes, which is accelerating the adoption of faecal calprotectin testing.

Point-of-Care Testing Expansion

Point-of-care (POC) testing is becoming increasingly popular in the Faecal Calprotectin Testing Market. The development of portable, easy-to-use test kits that provide rapid results at the point of care is a significant trend. These tests are designed to reduce wait times for results, making it easier for healthcare providers to make informed decisions without delays. For instance, Thermo Fisher Scientific offers POC faecal calprotectin test kits that provide quick and accurate results, facilitating prompt clinical decisions. As the demand for more convenient and efficient healthcare solutions grows, POC testing is expanding its reach across various healthcare settings, including hospitals, clinics, and even home care.

Personalized Medicine Approach

Another important trend is the growing shift towards personalized medicine in gastrointestinal healthcare. Faecal calprotectin testing plays a key role in this approach, as it allows clinicians to tailor treatment strategies based on an individual’s specific condition. By offering more precise monitoring of disease activity and inflammation levels, faecal calprotectin tests contribute to better management of chronic diseases like IBD. For instance, Genova Diagnostics uses faecal calprotectin testing as part of its personalized medicine approach to tailor treatment plans for patients with gastrointestinal conditions. This trend is gaining momentum as healthcare providers focus on optimizing treatment for each patient, reducing the use of unnecessary interventions and improving overall care quality.

Increasing Adoption in Emerging Markets

The adoption of faecal calprotectin testing is also expanding in emerging markets. As healthcare infrastructure improves and awareness of gastrointestinal diseases rises, countries in regions such as Asia-Pacific and Latin America are seeing a growing demand for advanced diagnostic tools. This trend is driven by the increasing prevalence of chronic gastrointestinal conditions, rising healthcare investments, and greater access to non-invasive diagnostic solutions. For instance, BIOHIT HealthCare has seen increased adoption of its faecal calprotectin test kits in emerging markets, helping improve gastrointestinal disease management and patient outcomes. The market is expected to continue growing in these regions as they recognize the value of early detection and monitoring in managing gastrointestinal diseases effectively.

Market Challenges Analysis

High Cost of Testing

One of the primary challenges in the Faecal Calprotectin Testing Market is the high cost associated with these tests, which can limit their accessibility, particularly in developing regions. The costs of testing kits, laboratory processing, and required follow-up consultations may pose a financial burden for both healthcare providers and patients. This is especially true in areas with limited healthcare resources or in countries where the healthcare system does not fully reimburse for diagnostic tests. Although faecal calprotectin testing is crucial for early detection and monitoring of gastrointestinal diseases, the high cost remains a significant barrier to widespread adoption, preventing some patients from benefiting from this diagnostic method. As a result, healthcare providers may hesitate to incorporate these tests into routine practice, which could hinder market growth. In addition, the need for specialized equipment and trained personnel to conduct the tests further increases the overall expenses, creating additional challenges in low-resource settings.

Regulatory and Standardization Challenges

Another challenge for the Faecal Calprotectin Testing Market lies in the lack of standardized testing protocols and variations in regulatory requirements across regions. While faecal calprotectin testing is widely recognized for its clinical value, the lack of universal standards for test accuracy and quality can lead to discrepancies in results, making it challenging for healthcare providers to rely on test outcomes consistently. Moreover, varying regulatory approval processes for new diagnostic technologies across different regions can slow down the introduction of innovative products and create barriers for manufacturers looking to enter new markets. Regulatory hurdles, along with the complex process of obtaining certifications and approvals for new diagnostic tests, can delay product launches and hinder the broader adoption of faecal calprotectin testing. Additionally, the inconsistency in reimbursement policies for these tests adds to the difficulty of implementing them at a larger scale, limiting their potential market reach. These challenges create roadblocks for companies trying to achieve broader distribution and adoption.

Market Segmentation Analysis:

By Assay

The Faecal Calprotectin Testing Market can be segmented by assay type into immunoassays, enzyme-linked immunosorbent assays (ELISA), and rapid test kits. Immunoassays are the most widely used due to their accuracy and reliability, while rapid test kits are gaining popularity for their convenience and speed. ELISA tests, though precise, are typically used in laboratory settings due to their complexity.

By Application

In terms of application, faecal calprotectin testing is primarily used for diagnosing inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. It also plays a critical role in colorectal cancer screening and monitoring disease activity. The ability to distinguish between IBD and irritable bowel syndrome (IBS) is driving the growth of this segment, enabling better clinical decision-making and patient management.

By End-Use

The Faecal Calprotectin Testing Market is further segmented by end-use into hospitals, diagnostic laboratories, and home care settings. Hospitals and diagnostic labs are the dominant end-users due to the advanced infrastructure and expertise required for conducting these tests. However, the growing trend of at-home testing solutions is pushing the adoption of faecal calprotectin testing in home care environments as well.

Segments:

Based on Assay

• Enzyme-linked Immunosorbent Assay
• Enzyme Fluroimmunoassay
• Quantitative Immunochromatography

Based on Application

• Inflammatory Bowel Disease
• Colorectal Cancer
• Others

Based on End-use

• Hospitals And Clinics
• Diagnostic Laboratories
• Academic And Research Institutes

Based on the Geography:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Regional Analysis

North America

North America holds a significant share of the Faecal Calprotectin Testing Market, driven by the high prevalence of gastrointestinal diseases such as inflammatory bowel disease (IBD) and colorectal cancer. The United States, in particular, represents a key market due to its advanced healthcare infrastructure, robust diagnostic technologies, and increasing adoption of non-invasive diagnostic methods. The growing awareness of gastrointestinal disorders and the rising demand for personalized healthcare solutions further contribute to the market’s growth in this region. In addition, the presence of major diagnostic companies and well-established healthcare policies in North America supports the widespread use of faecal calprotectin testing. The region is expected to maintain its dominance, holding a market share of 40% in the coming years.

Europe

Europe is another major market for faecal calprotectin testing, owing to the increasing incidence of gastrointestinal diseases, particularly in countries like Germany, France, and the UK. European healthcare systems emphasize preventive care and early diagnosis, further driving the demand for non-invasive diagnostic tests such as faecal calprotectin. The growing geriatric population in Europe also contributes to the rising need for effective diagnostic solutions. Furthermore, regulatory approvals and the widespread availability of advanced testing solutions in hospitals and diagnostic labs have fueled market expansion. Europe is projected to hold a market share of around 30%, with a steady growth rate due to the ongoing adoption of faecal calprotectin testing and continuous healthcare advancements.

Asia-Pacific

The Asia-Pacific region is expected to witness significant growth in the Faecal Calprotectin Testing Market, driven by the increasing healthcare investments and rising awareness of gastrointestinal diseases. Countries such as China, India, and Japan are experiencing a growing demand for diagnostic tools, fueled by the rising prevalence of chronic gastrointestinal conditions and an expanding healthcare infrastructure. The affordability of faecal calprotectin testing in these markets, coupled with the increasing adoption of non-invasive diagnostic methods, is propelling market growth. This region’s market share is anticipated to reach around 20% by 2032, with rapid expansion in both urban and rural areas.

Rest of the World

The Rest of the World (RoW), including regions such as Latin America, the Middle East, and Africa, holds a smaller market share but is seeing gradual growth. In these regions, the adoption of faecal calprotectin testing is influenced by factors like healthcare system development, economic conditions, and increasing awareness of gastrointestinal diseases. The market is expected to expand steadily as healthcare access improves and diagnostic capabilities increase across these regions. However, the market share remains limited compared to North America, Europe, and Asia-Pacific, estimated at around 10%.

Key Player Analysis

• Eagle Biosciences, Inc.
• Actim
• DRG International Inc.
• Svar Life Science
• ALPCO
• Epitope Diagnostics Inc.
• OPERON
• BÜHLMANN
• Hycult Biotech
• Diazyme Laboratories

Competitive Analysis

The Faecal Calprotectin Testing Market is highly competitive, with leading players striving to innovate and capture market share through product development and strategic partnerships. Companies like Epitope Diagnostics Inc., Hycult Biotech, Actim, Eagle Biosciences, Inc., OPERON, Svar Life Science, BÜHLMANN, DRG International Inc., ALPCO, and Diazyme Laboratories are actively enhancing their offerings by improving test accuracy, speed, and ease of use. These companies focus on expanding their global presence through collaborations and distribution agreements, especially in emerging markets. For instance, Hycult Biotech has formed strategic partnerships with distributors in Asia-Pacific to expand its market reach and improve accessibility to its testing solutions. Additionally, the emphasis on non-invasive diagnostic methods and personalized healthcare solutions is driving product differentiation. Competitive strategies also include investments in research and development to bring more advanced, cost-effective, and reliable testing solutions to the market. With growing demand for early disease detection, these players are focused on enhancing customer trust, expanding their product portfolios, and tapping into new geographical regions.

Recent Developments

• In July 2023, Thermo Fisher Scientific Inc. completed the acquisition of CorEvitas, LLC, a leading provider of high-quality, real-world evidence for authorized medical treatments and therapies, from Audax Private Equity for $912.5 million in cash. Thermo Fisher confirmed the deal to acquire CorEvitas.
• In May 2024, the Allen Institute for Immunology and Seattle Children’s Research Institute launched a study focused on exploring the molecular complexities of pediatric inflammatory bowel disease (IBD). The research will use various genomic technologies to analyze intact tissue samples obtained from standard diagnostic tests, utilizing single-cell analysis techniques to gain deeper insights into immune system dynamics in IBD patients and track their immune responses to specific drug therapies over time.

Market Concentration & Characteristics

The Faecal Calprotectin Testing Market exhibits moderate concentration, with a mix of established players and emerging companies competing for market share. Leading companies have developed strong brand recognition, advanced technologies, and robust distribution networks, enabling them to maintain a dominant position in the market. However, the presence of smaller players focusing on niche segments or offering cost-effective solutions also contributes to a competitive landscape. Market characteristics are influenced by increasing demand for non-invasive diagnostic methods, growing awareness of gastrointestinal diseases, and advancements in healthcare technologies. Companies in the market are emphasizing innovation, with a focus on enhancing the accuracy, speed, and user-friendliness of faecal calprotectin tests. The market is also characterized by strategic collaborations, partnerships, and acquisitions, which help companies expand their geographical reach and product portfolios. As the demand for personalized healthcare grows, companies are likely to focus more on tailored diagnostic solutions and market diversification.

Report Coverage

The research report offers an in-depth analysis based on Assay, End-Use, Application and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. The Faecal Calprotectin Testing Market is expected to witness steady growth driven by the increasing prevalence of gastrointestinal diseases.
2. Non-invasive diagnostic methods will continue to gain popularity, making faecal calprotectin testing a preferred choice for early disease detection.
3. Technological advancements will lead to more accurate, faster, and cost-effective testing solutions.
4. The market will see growing adoption of point-of-care testing devices, improving accessibility and convenience for patients.
5. Increased awareness and early diagnosis of inflammatory bowel diseases (IBD) and colorectal cancer will fuel demand for faecal calprotectin tests.
6. Expanding healthcare infrastructure in emerging markets will create new growth opportunities for diagnostic companies.
7. The integration of digital health solutions and mobile apps for test result monitoring will become more widespread.
8. Personalized medicine trends will drive the need for precise and tailored diagnostic tools, further boosting market demand.
9. Partnerships and collaborations among key market players will enhance product portfolios and accelerate market penetration.
10. The growing focus on preventive healthcare will likely increase the use of faecal calprotectin testing for routine screenings and monitoring.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.